解脲支原体
医学
红霉素
绒毛膜羊膜炎
解脲支原体
产科
低出生体重
安慰剂
妊娠期
出生体重
胎龄
沙眼衣原体
胎膜早破
怀孕
随机对照试验
抗生素
内科学
支原体
妇科
微生物学
遗传学
替代医学
病理
生物
作者
David A. Eschenbach,Robert P. Nugent,A. R. Rao,Mary Frances Cotch,Ronald S. Gibbs,Kathleen A. Lipscomb,David C. Martin,Joseph G. Pastorek,Philip J. Rettig,J. William Carey,Joan A. Regan,Kim Geromanos,Molly N. N. Lee,W. Kenneth Poole,Robert R. Edelman
标识
DOI:10.1016/0002-9378(91)90506-m
摘要
Ureaplasma urealyticum has been associated with low birth weight and histologic chorioamnionitis and it is a frequent isolate from the chorioamnion of patients who are delivered prematurely. In prior clinical trials using antibiotics active against U. urealyticum, antibiotic treatment was associated with reduced prematurity and increased mean birth weight. In this multicenter, randomized, double-blind clinical trial, pregnant women with U. urealyticum were treated with 333 mg of erythromycin base or placebo three times daily, starting between 26 and 30 weeks' gestation and continuing through 35 completed weeks of pregnancy. Women with urinary tract infection or Neisseria gonorrhoeae infection were excluded from the trial, and women with Chlamydia trachomatis or group B streptococci were excluded from these analyses. Erythromycin did not eliminate U. urealyticum from the lower genital tract. There were no significant differences between erythromycin- and placebo-treated women in infant birth weight or gestational age at delivery, in frequency of premature rupture of membranes, or in neonatal outcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI